Drug Profile

ADR 002

Alternative Names: ADR-002; ADR-002K

Latest Information Update: 26 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Osaka University Hospital; Rohto Pharmaceutical
Class Cardiovascular therapies; Gene therapies; Mesenchymal stem cell therapies; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Chronic heart failure
Phase I Cardiomyopathies

Most Recent Events

28 Apr 2026 Phase-II clinical trials in Chronic heart failure in Japan (Parenteral) (NCT07192211)
25 Sep 2025 ADR 002 is still in phase I trials for cardiomyopathies in Japan.
25 Sep 2025 Rohto Pharmaceuticals plans a phase II trial for Chronic heart failure in an unknown location in September 2025 (NCT07192211) (jRCT2053250022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com